Tag team wrestling

Regulation

Increased collaboration between FDA and SEC, fallout from the ImClone Systems Inc. case, and investor demands for more information about early-stage drug development, are contributing to an intensification of SEC's scrutiny of public disclosures by biopharmaceutical companies. Biotech companies are receiving more queries from SEC, and the questions are far more technical, according to attorneys who specialize in handling securities issues for biotech companies. ...